Status:
COMPLETED
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome
Lead Sponsor:
Francis Corazza
Conditions:
COVID-19
Eligibility:
All Genders
Phase:
NA
Brief Summary
In patients infected by the SARS-Cov-2 Coronavirus a severely progressive disease requiring hospitalization in intensive care seems related to deregulation of cytokines with very high levels of IL-6, ...
Detailed Description
In patients with severely progressive SARS-Cov-2 Coronavirus infection, the elderly and immunocompromised are at greater risk of progressing to a serious image of ARDS (Acute Respiratory Distress synd...
Eligibility Criteria
Inclusion
- End of the initial phase of high viral load of SARS-Cov-2 (for example apyretic\> 72h and / or at least 7 days after the onset of symptoms)
- Worsening of respiratory exchanges which require non-invasive or invasive ventilation support (BCRSS score ≥3)
- High levels of IL-6 (\> 40 pg / ml); alternatively high levels of d-dimer and / or PCR and / or ferritin and / or fibrinogen gradually increase.
- A control group will be formed by patients in the Covid unit who do not have respiratory problems justifying a transfer to intensive care.
Exclusion
- Documented sepsis caused by other pathogens other than SARS-Corv-2.
- Presence of comorbidities likely to lead, according to clinical judgment, to an unfavorable result
- Immunosuppressive anti-rejection therapy
Key Trial Info
Start Date :
March 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2020
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04346017
Start Date
March 20 2020
End Date
November 23 2020
Last Update
September 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020